Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals is experiencing strong revenue and earnings growth, with 1H26 revenue increasing by 22% year-over-year and adjusted EBITDA increasing by 26% year-over-year. In addition, the company's diagnostics franchise, particularly Illuccix, is gaining market share, and the company's therapeutics pipeline continues to progress toward value-inflecting datasets. With multiple diagnostic approvals and expansions on the horizon, as well as a strong pipeline of therapeutics, Telix is positioned for future success and its shares are currently undervalued.

Bears say

Telix Pharmaceuticals is projected to see a significant growth in its pipeline with its radiopharmaceuticals targeting cancer, which could potentially increase the company's revenue in the future. However, its current earnings are heavily dependent on the US sales of Illuccix as an imaging agent, leaving the company vulnerable to potential market shifts. Additionally, its valuation based on a sum-of-parts and discounted future sales projections may be inflated and not entirely reflective of the current financial health of the company.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.